Safety recommendation
HSIB recommends that the National Institute for Health and Care Excellence reviews the findings of this investigation in relation to its guidance NG158, ‘Venous thromboembolic diseases: diagnosis, management and thrombophilia testing’, and updates the guidance if required.
Response:
We have considered the report and noted the specific concerns that have been raised in relation to our guideline on venous thromboembolic diseases: diagnosis, management and thrombophilia testing [NG158]. We propose to undertake an exceptional surveillance review of the guideline to see if an update to our recommendations is required.
The review has been scheduled into the guideline surveillance team’s programme of work and we expect to complete this in summer 2022. I would like to assure you that we recognise the importance of the HSIB’s recommendation and will ensure that any actions identified by the surveillance review are prioritised.
The National Institute for Health and Care Excellence (NICE) has committed to review its guideline on venous thromboembolic diseases: diagnosis, management and thrombophilia testing [NG158]. It will consider if an update to its recommendations is needed.
Actions planned to deliver safety recommendation:
- Undertake an exceptional surveillance review of the NICE guideline on venous thromboembolic diseases: diagnosis, management and thrombophilia testing [NG158]. BY: Summer 2022. Resources in place: Project staff from the surveillance team. Other dependencies identified: The review will be scheduled in the surveillance team’s work programme as soon as possible, taking into account NICE’s existing workload and agreed priorities.
- Update NG158 if the exceptional surveillance review indicates this is required. BY: TBC. Other dependencies identified: An update is dependent on the outcome of the exceptional surveillance review.
Response received on 20 June 2022.